Welcome to our dedicated page for Organogenesis Hldgs SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Organogenesis Holdings Inc.'s SEC filings document a regenerative medicine issuer with Class A common stock listed on the Nasdaq Capital Market. The filings cover operating and financial results for Advanced Wound Care and Surgical & Sports Medicine products, including furnished 8-K earnings releases that separate product revenue by market category.
The company's regulatory record also includes proxy materials for annual meeting matters, director elections, advisory voting items, board governance and compensation disclosures. Other filings address Regulation FD and material-event updates for ReNu clinical and regulatory matters, capital-structure details involving Class A common stock and Series A Convertible Preferred Stock voting mechanics, and risk and governance topics tied to its product portfolio.
Organogenesis Holdings Inc. reported a sharp downturn for the quarter ended March 31, 2026. Net product revenue fell to $36.3 million from $86.7 million, driven mainly by a steep decline in Advanced Wound Care sales linked to Medicare reimbursement changes and clinician confusion.
Total revenue was $37.2 million, while the company posted a net loss of $53.2 million versus $18.8 million a year earlier, with gross profit compressing significantly. Adjusted EBITDA worsened to a loss of $48.2 million, reflecting lower volume, pricing pressure, inventory write-downs and restructuring costs.
The company implemented a March 2026 restructuring, closing its St. Petersburg, Florida facility and reducing headcount by about 10%, recording $8.8 million of related charges. Despite losses, Organogenesis ended the quarter with $91.4 million in cash and access to a $75.0 million undrawn revolving credit facility, and continues investing in its Smithfield, Rhode Island biomanufacturing build-out and ReNu biologics license application.
Organogenesis Holdings Inc. reported a steep downturn for the first quarter ended March 31, 2026. Net product revenue fell to $36.3 million from $86.7 million a year earlier, a 58% decline, driven by a 63% drop in Advanced Wound Care revenue to $29.5 million. Gross profit fell to $10.5 million, or 29% of net product revenue, from $63.0 million, or 73%. Operating loss widened to $68.9 million and net loss to $53.2 million, or $(0.44) per share, compared with a $18.8 million net loss, or $(0.17) per share, in 2025. Adjusted EBITDA loss increased to $48.2 million from $12.5 million. Despite the weak quarter, the company ended March 31, 2026 with $92.1 million in cash, cash equivalents and restricted cash and no outstanding debt, and issued full-year 2026 revenue guidance of $270.0 million to $310.0 million, implying a 45% to 52% decline from 2025.
Organogenesis Holdings Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 15, 2026 at 11:00 a.m. Eastern. Investors will elect nine common directors, cast an advisory say-on-pay vote on 2025 executive compensation, and ratify RSM US LLP as independent auditor for 2026.
As of April 23, 2026, 128,674,548 shares of Common Stock and 130,000 shares of Convertible Preferred Stock, convertible into 38,470,359 Common shares, were entitled to vote together. Preferred holders can elect one board member while they hold at least 5% of the as-converted Common. Executive pay blends base salary, annual cash bonuses tied mainly to net revenue and Adjusted EBITDA, and long-term equity including stock options, RSUs and new performance share awards, which in 2025 vested at the maximum level for the first tranche based on revenue growth.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share. The option was fully vested and, after the transaction, he directly holds 900,682 shares.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at a price of $2.681 per share on March 9, 2026. Following this transaction, his directly held stake increased to 291,014 shares.
Organogenesis Holdings Inc. director Michael Joseph Driscoll bought 10,000 shares of Class A Common Stock in an open-market purchase. He paid about $2.67 per share, for a total of roughly $26,688. Following this transaction, he directly owns 225,707 shares, making this a relatively small addition to his stake.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported a tax-related share transfer. On this transaction, 700 shares of Class A common stock were disposed of at $3.21 per share to cover tax withholding obligations, leaving him with 275,524 directly held shares.
Organogenesis Holdings Inc. executive Antonio S. Montecalvo reported updated stock transactions related to an equity award. The amended filing corrects the number of Class A Common shares acquired upon vesting of a performance share award and the shares withheld to cover taxes. On February 18, 2026, he was granted 11,330 shares at a price of $0.00 per share and had 3,778 shares withheld at $3.84 per share to satisfy tax obligations. After these adjustments, he directly holds 226,238 Class A Common shares. The amendment states no other changes were made to the original report.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.